1 |
Ro5333787 |
- |
- |
- |
- |
013 [1] 13 💬 |
2 |
Satralizumab (ro5333787/enspryng /sa237) |
Satralizumab |
[1] D11079 D11079 💬 |
IL6R [1] IL6R 💬 |
Coronavirus disease - COVID-19 [12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
013 [1] 13 💬 |
3 |
Satralizumab (ro5333787/enspryng/sa237) |
Satralizumab |
[1] D11079 D11079 💬 |
IL6R [1] IL6R 💬 |
Coronavirus disease - COVID-19 [12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
013 [1] 13 💬 |
4 |
Satralizumab (ro5333787/sa237) |
Satralizumab |
[1] D11079 D11079 💬 |
IL6R [1] IL6R 💬 |
Coronavirus disease - COVID-19 [12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
013 [1] 13 💬 |
5 |
Satrazlizumab (ro5333787/ enspryng /sa237) |
- |
- |
- |
- |
013 [1] 13 💬 |